|
Jun 3
|
ASCO25: Genmab’s Rina-S en route to ‘blockbuster potential’ amid further positive data
|
|
Jun 2
|
Why Genmab Stock Smashed It on Monday
|
|
Jun 2
|
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
|
|
May 30
|
Genmab price target lowered to DKK 2,000 from DKK 2,300 at RBC Capital
|
|
Apr 16
|
GMAB or RGEN: Which Is the Better Value Stock Right Now?
|
|
Apr 16
|
Should Value Investors Buy Genmab (GMAB) Stock?
|
|
Apr 15
|
Genmab (CPSE:GMAB) Reports US$3 Billion DARZALEX Sales For Q1 2025
|
|
Apr 15
|
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025
|
|
Apr 10
|
Genmab A/S Share Capital Reduction
|
|
Mar 28
|
Genmab’s Tivdak approved in Japan for advanced cervical cancer
|
|
Mar 27
|
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
|
|
Mar 27
|
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
|
|
Feb 25
|
Genmab A/S (GMAB): Among the Stocks That Will Go to the Moon According to Analysts
|
|
Feb 24
|
Is Genmab (GMAB) One of the Best Growth Stocks to Invest In According to Analysts?
|
|
Feb 20
|
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
|
|
Feb 19
|
Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference
|
|
Feb 13
|
Why Genmab (GMAB) and Sonic Automotive (SAH) Are Advancing Today
|
|
Feb 13
|
Genmab AS (GMAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...
|
|
Feb 12
|
Genmab Publishes 2024 Annual Report
|
|
Jan 3
|
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference
|